Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
Completed
- Conditions
- HypercholesterolemiaHyperlipidemiaCoronary Heart Disease
- Interventions
- Registration Number
- NCT00723723
- Lead Sponsor
- Organon and Co
- Brief Summary
This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 555
Inclusion Criteria
- willingness to participate in the study
- 18 years of age or more
- clinically established cardiovascular disease to be considered as patients in secondary prevention
- prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol) at last lipid check performed
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with coronary heart disease Statin Patients being treated with a statin for secondary prevention of coronary heart disease
- Primary Outcome Measures
Name Time Method percentage of patients reaching target LDL levels 6-8 weeks after first visit and 28-32 weeks after first visit
- Secondary Outcome Measures
Name Time Method measure patient compliance to treatment as assessed by counting returned tablets 6-8 weeks after first visit and 28-32 weeks after first visit